Some eight months after its launch, companies are still not using England’s £340m ($407m) Innovative Medicines Fund (IMF) to get their new non-cancer drugs to patients because it carries too much risk, says Sean Richardson, vice-president and general manager for the UK and Ireland at Alexion Pharmaceuticals Inc..
Launched in June 2022, the IMF was designed to offer conditional reimbursement for innovative new non-cancer drugs that are associated...








